JP2019506155A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019506155A5 JP2019506155A5 JP2018537533A JP2018537533A JP2019506155A5 JP 2019506155 A5 JP2019506155 A5 JP 2019506155A5 JP 2018537533 A JP2018537533 A JP 2018537533A JP 2018537533 A JP2018537533 A JP 2018537533A JP 2019506155 A5 JP2019506155 A5 JP 2019506155A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence
- homology
- domain
- binding molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 claims description 49
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 claims description 49
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims description 47
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims description 39
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 claims description 39
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 32
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims description 29
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims description 29
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 27
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 108020004707 nucleic acids Proteins 0.000 claims description 9
- 150000007523 nucleic acids Chemical class 0.000 claims description 9
- 102000039446 nucleic acids Human genes 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 208000017497 prostate disease Diseases 0.000 claims description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 102000046689 human FOLH1 Human genes 0.000 claims description 3
- 238000011830 transgenic mouse model Methods 0.000 claims description 3
- 101150117115 V gene Proteins 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 230000003053 immunization Effects 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 101100434411 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) ADH1 gene Proteins 0.000 description 1
- 101150102866 adc1 gene Proteins 0.000 description 1
- 101150042711 adc2 gene Proteins 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021211614A JP7450594B2 (ja) | 2016-01-12 | 2021-12-24 | 治療分子 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1600559.7 | 2016-01-12 | ||
| GBGB1600559.7A GB201600559D0 (en) | 2016-01-12 | 2016-01-12 | Therapeutic molecules |
| GB1605770.5 | 2016-04-04 | ||
| GB1605763.0 | 2016-04-04 | ||
| GB201605763 | 2016-04-04 | ||
| GB201605770 | 2016-04-04 | ||
| PCT/GB2017/050074 WO2017122017A1 (en) | 2016-01-12 | 2017-01-12 | Therapeutic molecules |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021211614A Division JP7450594B2 (ja) | 2016-01-12 | 2021-12-24 | 治療分子 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019506155A JP2019506155A (ja) | 2019-03-07 |
| JP2019506155A5 true JP2019506155A5 (enExample) | 2020-02-27 |
Family
ID=57838417
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018537533A Pending JP2019506155A (ja) | 2016-01-12 | 2017-01-12 | 治療分子 |
| JP2018537519A Active JP7190901B2 (ja) | 2016-01-12 | 2017-01-12 | 前立腺特異的膜抗原（ｐｓｍａ）と結合する分子 |
| JP2021211614A Active JP7450594B2 (ja) | 2016-01-12 | 2021-12-24 | 治療分子 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018537519A Active JP7190901B2 (ja) | 2016-01-12 | 2017-01-12 | 前立腺特異的膜抗原（ｐｓｍａ）と結合する分子 |
| JP2021211614A Active JP7450594B2 (ja) | 2016-01-12 | 2021-12-24 | 治療分子 |
Country Status (5)
| Country | Link |
|---|---|
| US (4) | US11236174B2 (enExample) |
| EP (2) | EP3402824A1 (enExample) |
| JP (3) | JP2019506155A (enExample) |
| CN (3) | CN108473590B (enExample) |
| WO (3) | WO2017122019A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108473590B (zh) | 2016-01-12 | 2023-04-14 | 克雷森多生物制剂有限公司 | 治疗分子 |
| GB201607968D0 (en) | 2016-05-06 | 2016-06-22 | Crescendo Biolog Ltd | Chimeric antigen receptor |
| WO2018127710A1 (en) | 2017-01-06 | 2018-07-12 | Crescendo Biologics Limited | Single domain antibodies to programmed cell death (pd-1) |
| GB201711068D0 (en) * | 2017-07-10 | 2017-08-23 | Crescendo Biologics Ltd | Therapeutic molecules binding PSMA |
| CN111683968B (zh) | 2017-11-13 | 2024-07-05 | 克雷森多生物制剂有限公司 | 结合至cd137和psma的分子 |
| GB201802573D0 (en) | 2018-02-16 | 2018-04-04 | Crescendo Biologics Ltd | Therapeutic molecules that bind to LAG3 |
| GB201818460D0 (en) * | 2018-11-13 | 2018-12-26 | Crescendo Biologics Ltd | Single domain antibodies that bind human serum albumin |
| CN113710707B (zh) * | 2019-04-05 | 2024-05-31 | 特尼奥生物股份有限公司 | 结合于psma的重链抗体 |
| KR102260478B1 (ko) * | 2019-08-19 | 2021-06-02 | 연세대학교 산학협력단 | 일나트륨 요소화물 결정 용해용 조성물 |
| CN111303288B (zh) * | 2020-03-04 | 2020-12-25 | 和铂医药(苏州)有限公司 | 一种分离的结合抗原psma的蛋白及其用途 |
| MX2023000448A (es) | 2020-07-08 | 2023-04-20 | Lava Therapeutics N V | Anticuerpos que se unen a antígeno de membrana específico de la próstata (psma) y receptores de celulas t gamma-delta. |
| CN112480260B (zh) * | 2020-12-09 | 2022-03-08 | 福州迈新生物技术开发有限公司 | 抗psma蛋白单克隆抗体、细胞系及其制备方法和应用 |
| AU2022226277A1 (en) * | 2021-02-25 | 2023-08-31 | Teneobio, Inc. | Anti-psma antibodies and car-t structures |
| CA3230346A1 (en) * | 2021-08-27 | 2023-03-02 | Janssen Biotech, Inc. | Anti-psma antibodies and uses thereof |
| WO2023199069A1 (en) | 2022-04-14 | 2023-10-19 | Crescendo Biologics Limited | Chimeric antigen receptor that binds mesothelin |
| GB202205589D0 (en) | 2022-04-14 | 2022-06-01 | Crescendo Biologics Ltd | Mesothelin binders |
| GB202214528D0 (en) | 2022-10-03 | 2022-11-16 | Owlstone Med Ltd | A compound |
| CN116271081A (zh) * | 2023-04-04 | 2023-06-23 | 上海愿智生物技术有限公司 | 一种抗体偶联药物yc1605及其药物组合物和应用 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0115256D0 (en) | 2001-06-21 | 2001-08-15 | Babraham Inst | Mouse light chain locus |
| ES2606537T3 (es) | 2001-10-23 | 2017-03-24 | Psma Development Company L.L.C. | Anticuerpos contra PSMA |
| US20050215472A1 (en) | 2001-10-23 | 2005-09-29 | Psma Development Company, Llc | PSMA formulations and uses thereof |
| GB2398784B (en) | 2003-02-26 | 2005-07-27 | Babraham Inst | Removal and modification of the immunoglobulin constant region gene cluster of a non-human mammal |
| GB0313132D0 (en) | 2003-06-06 | 2003-07-09 | Ich Productions Ltd | Peptide ligands |
| GB0316294D0 (en) | 2003-07-11 | 2003-08-13 | Polytherics Ltd | Conjugated biological molecules and their preparation |
| JP2008529556A (ja) | 2005-02-18 | 2008-08-07 | メダレックス， インク． | 前立腺特異的膜抗原（ｐｓｍａ）に対するヒトモノクローナル抗体 |
| CA2616859C (en) | 2005-08-03 | 2015-04-14 | Fraunhofer Usa, Inc. | Compositions and methods for production of immunoglobulins |
| EP2209494B1 (en) | 2007-10-09 | 2016-07-20 | Polytherics Limited | Novel conjugated proteins and peptides |
| US20100122358A1 (en) | 2008-06-06 | 2010-05-13 | Crescendo Biologics Limited | H-Chain-only antibodies |
| WO2013045916A1 (en) | 2011-09-26 | 2013-04-04 | Kymab Limited | Chimaeric surrogate light chains (slc) comprising human vpreb |
| CA2863799C (en) | 2012-02-22 | 2020-09-01 | Matthew J. FRIGAULT | Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer |
| CN103087171B (zh) | 2012-12-24 | 2015-01-14 | 中国人民解放军第四军医大学 | 一种用于前列腺癌早期诊断和治疗的抗psma/fitc双特异性抗体及其制备方法 |
| WO2014141192A1 (en) | 2013-03-15 | 2014-09-18 | Erasmus University Medical Center | Generation of heavy chain-only antibodies |
| CN103333249A (zh) | 2013-06-14 | 2013-10-02 | 广州康合生物科技有限公司 | 一种抗前列腺特异性膜抗原（psma）的单克隆抗体及其应用 |
| WO2015142675A2 (en) | 2014-03-15 | 2015-09-24 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
| TWI701042B (zh) * | 2014-03-19 | 2020-08-11 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| JP6919118B2 (ja) | 2014-08-14 | 2021-08-18 | ノバルティス アーゲー | ＧＦＲα−４キメラ抗原受容体を用いる癌の治療 |
| GB2547587B (en) | 2014-10-22 | 2020-12-09 | Crescendo Biologics Ltd | Transgenic mice |
| EP3220956B1 (en) | 2014-10-24 | 2023-08-09 | Abzena (UK) Limited | Conjugates and conjugating reagents |
| CN105384825B (zh) | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
| CN108473590B (zh) | 2016-01-12 | 2023-04-14 | 克雷森多生物制剂有限公司 | 治疗分子 |
| CN105968204B (zh) | 2016-02-03 | 2020-01-21 | 中国人民解放军第三军医大学第一附属医院 | 一种抗前列腺特异性膜抗原的单域重链抗体 |
| CN105968205B (zh) | 2016-02-03 | 2019-04-26 | 中国人民解放军第三军医大学第三附属医院 | 一种抗前列腺特异性膜抗原的纳米抗体 |
| CN105968203A (zh) | 2016-02-03 | 2016-09-28 | 南昌大学 | 一种抗前列腺特异性膜抗原胞外区的单域重链抗体 |
| GB201607968D0 (en) | 2016-05-06 | 2016-06-22 | Crescendo Biolog Ltd | Chimeric antigen receptor |
| GB201711068D0 (en) | 2017-07-10 | 2017-08-23 | Crescendo Biologics Ltd | Therapeutic molecules binding PSMA |
| CN111683968B (zh) | 2017-11-13 | 2024-07-05 | 克雷森多生物制剂有限公司 | 结合至cd137和psma的分子 |
-
2017
- 2017-01-12 CN CN201780006538.5A patent/CN108473590B/zh active Active
- 2017-01-12 EP EP17700734.1A patent/EP3402824A1/en active Pending
- 2017-01-12 CN CN202310315828.5A patent/CN116478293A/zh active Pending
- 2017-01-12 JP JP2018537533A patent/JP2019506155A/ja active Pending
- 2017-01-12 JP JP2018537519A patent/JP7190901B2/ja active Active
- 2017-01-12 CN CN201780006227.9A patent/CN108473589B/zh active Active
- 2017-01-12 WO PCT/GB2017/050076 patent/WO2017122019A1/en not_active Ceased
- 2017-01-12 WO PCT/GB2017/050074 patent/WO2017122017A1/en not_active Ceased
- 2017-01-12 US US16/069,497 patent/US11236174B2/en active Active
- 2017-01-12 WO PCT/GB2017/050075 patent/WO2017122018A1/en not_active Ceased
- 2017-01-12 EP EP17701006.3A patent/EP3402825A1/en not_active Withdrawn
- 2017-01-12 US US16/069,495 patent/US10975161B2/en active Active
-
2021
- 2021-10-22 US US17/508,583 patent/US11746158B2/en active Active
- 2021-12-24 JP JP2021211614A patent/JP7450594B2/ja active Active
-
2023
- 2023-06-28 US US18/343,126 patent/US20230406954A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019506155A5 (enExample) | ||
| JP2020530285A5 (enExample) | ||
| JP7209464B2 (ja) | ヒトインターロイキン－２に対する免疫刺激性モノクローナル抗体 | |
| ES2657458T3 (es) | Procedimientos para tratar el cáncer colorrectal | |
| JP2019511201A5 (enExample) | ||
| JP2012518425A5 (enExample) | ||
| JP2022509930A (ja) | 抗ｃｄ７３抗体、その抗原結合フラグメントおよびそれらの使用 | |
| JP2017532005A5 (enExample) | ||
| JP2020500003A5 (enExample) | ||
| JP2017526339A5 (enExample) | ||
| JP2020515251A (ja) | Ｂ７−ｈ３抗体、その抗原結合フラグメント、及びそれらの医学的使用 | |
| JP2017519501A5 (enExample) | ||
| JP2014518615A5 (enExample) | ||
| RU2017107773A (ru) | Антитела, специфичные к ммр9 | |
| JP2020534830A5 (enExample) | ||
| CN110914304A (zh) | Cd96抗体、其抗原结合片段及医药用途 | |
| JP2021530207A (ja) | 二重特異性抗体及びその使用 | |
| CN111533805B (zh) | 一种抗癌胚抗原的高亲和力纳米抗体及其应用 | |
| CN112574308A (zh) | 靶向bcma的抗体、双特异性抗体及其用途 | |
| JP2017538439A5 (enExample) | ||
| Xia et al. | Preparation and characterization of anti-GPC3 nanobody against hepatocellular carcinoma | |
| CN108178799B (zh) | 一种抗ca125糖类抗原的纳米抗体及其应用 | |
| JP2014515600A5 (enExample) | ||
| CN101440130A (zh) | 一种抗人IL-13Rα2单克隆抗体的重链和轻链的可变区 | |
| CN113227148B (zh) | 抗gpc3抗体、其抗原结合片段及其医药用途 |